Peak Planning Group LLC Takes $882,000 Position in VanEck Pharmaceutical ETF $PPH

Peak Planning Group LLC bought a new stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,548 shares of the company’s stock, valued at approximately $882,000. Peak Planning Group LLC owned 0.08% of VanEck Pharmaceutical ETF as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in PPH. AlphaCore Capital LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the fourth quarter valued at approximately $31,000. Group One Trading LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the fourth quarter valued at approximately $36,000. IFP Advisors Inc increased its stake in shares of VanEck Pharmaceutical ETF by 53.7% during the third quarter. IFP Advisors Inc now owns 438 shares of the company’s stock valued at $40,000 after buying an additional 153 shares during the period. Advisory Services Network LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the third quarter valued at approximately $41,000. Finally, REAP Financial Group LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the fourth quarter valued at approximately $52,000.

VanEck Pharmaceutical ETF Stock Performance

PPH opened at $106.47 on Friday. VanEck Pharmaceutical ETF has a 52-week low of $81.74 and a 52-week high of $112.58. The stock has a market capitalization of $1.01 billion, a PE ratio of 20.21 and a beta of 0.47. The stock’s 50 day moving average price is $103.01 and its 200-day moving average price is $104.35.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Wednesday, April 1st were paid a $0.8441 dividend. The ex-dividend date of this dividend was Wednesday, April 1st. This is a positive change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31. This represents a $3.38 annualized dividend and a yield of 3.2%.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.